An approved investigational device exemption (IDE) permits a device to be:
An Investigational Device Exemption (IDE) allows an unapproved medical device to be used in a clinical investigation.
21 CFR 812.1(a): ''An approved IDE permits a device to be shipped lawfully for the purpose of conducting investigations of the device without complying with other requirements of the Food, Drug, and Cosmetic Act that would otherwise apply.''
It does not allow commercial sale (B), non-study clinical use (C), or marketing as a humanitarian device (D).
Thus, the correct answer is A (Shipped lawfully for clinical study).
21 CFR 812.1(a) (IDE exemption provisions).
After completion of a Phase III trial, which document should IRB/IEC retain?
21 CFR 56.115(a)(5): IRBs must retain records of IRB membership (names, qualifications, affiliations, occupations).
Other documents (contracts, enrollment logs, product labels) are site or sponsor responsibilities, not IRB's.
The FDA may propose to terminate an IND during a Phase I study if the FDA finds that which of the following conditions exists?
The FDA has authority to impose clinical holds and terminations on IND studies when subject safety is at risk.
21 CFR 312.44(b)(1): ''The FDA may propose to terminate an IND if it finds that human subjects would be exposed to an unreasonable and significant risk of illness or injury.''
21 CFR 312.42(e): ''If an IND is placed on clinical hold and the deficiencies have not been adequately addressed within 30 days, FDA may terminate the IND.''
Annual reports (A) are required but noncompliance usually results in clinical hold, not immediate termination. IRB approval delays (B) do not trigger termination; the site simply cannot begin. Investigators report safety data to sponsors, not directly to FDA (C).
Thus, the correct answer is D (The FDA issued a clinical hold, and 30 days have elapsed).
21 CFR 312.44(b)(1) (Termination of an IND).
21 CFR 312.42(e) (Clinical hold procedures).
According to ICH GCP, who besides the sponsor should approve the financial aspects of a clinical trial?
ICH E6(R2) 5.6.1: ''The sponsor should ensure agreement from the investigator/institution on the financial aspects of the trial.''
This ensures transparency in compensation, reimbursement, and budget.
An investigator received an updated investigator's brochure from the sponsor; the update did not include changes related to subject safety. Which of the following parties, if any, is the investigator required to notify?
The Investigator's Brochure (IB) is updated by the sponsor to reflect new scientific or clinical information.
ICH E6(R2) 7.3: ''The sponsor should revise the IB as soon as new, significant information becomes available.''
ICH E6(R2) 4.1.5: Requires the investigator to ensure staff are informed, but there is no requirement to notify IRB/IEC unless subject safety, rights, or risk profile is affected.
Since this update contained no changes related to subject safety, the investigator is not obligated to notify IRB/IEC, DSMB, or regulators. The updated IB must simply be filed in the regulatory binder and implemented at the site.
Thus, the correct answer is D (No notification is required).
ICH E6(R2), 7.3 (Updating the Investigator's Brochure).
ICH E6(R2), 4.1.5 (Investigator responsibilities for informing staff).
Dennis Young
11 days agoNathan Nelson
26 days agoOlivia Morris
1 month agoDaniel Rivera
2 months agoJustin Garcia
2 months agoJennifer Mitchell
3 months agoTiffany Davis
3 months agoFrank Edwards
3 months agoBarbara Turner
2 months agoJustin Turner
2 months agoDonald Rogers
2 months agoLoren
3 months agoBelen
4 months agoTerrilyn
4 months agoLeila
4 months agoCarol
4 months agoMadelyn
5 months agoDong
5 months agoShannan
5 months agoLatrice
5 months agoLai
6 months agoJackie
6 months agoDaren
6 months agoIzetta
6 months agoFrancesco
7 months agoGlynda
7 months agoArminda
7 months agoRory
7 months agoHyun
8 months agoTasia
8 months agoTaryn
8 months agoShelba
8 months agoLuann
9 months agoLai
9 months agoDorsey
9 months agoAnisha
9 months agoIluminada
10 months ago